Effect of Combined Oral Contraceptives on Breast Epithelial Proliferation in Young Women
- 1 September 2008
- journal article
- research article
- Published by Hindawi Limited in The Breast Journal
- Vol. 14 (5), 450-455
- https://doi.org/10.1111/j.1524-4741.2008.00621.x
Abstract
The mammary gland undergoes morphologic changes during the menstrual cycle. Proliferation of normal breast epithelium is most extensive during the natural luteal phase. To determine the impact of one cycle of a combined oral contraceptive (COC) on breast homeostasis, we evaluated the proliferation index (PI), determined by KI-67 expression, in normal human mammary epithelial cells and correlated it with cellular proliferation in spontaneous menstrual cycles during the same period. Normal breast tissue samples were obtained from 82 patients randomized in two groups. Forty-two women in group A received one cycle of a COC (30 mu g ethinyl estradiol and 150 mu g levonorgestrel) administrated daily for 21 days, beginning on the first day of the menstrual cycle. Group B patients (n = 40) experienced a natural menstrual cycle. Menstrual cycle phase characterization was based on the date of the last period and subsequent menses and on progesterone serum levels obtained at the time of biopsy. the PI (number of Ki-67-positive nuclei per 1,000 epithelial cells), was significantly larger in group A (5.47 +/- 3.87), than in group B (3.27 +/- 3.24), p < 0.01. A cyclical variation of PI was observed in COC cycles. the rise in PI in the first week of the COC cycles was significantly higher than in the natural cycle (COC = 7.02 +/- 4.94; non-COC = 1.10 +/- 0.67; p < 0.0011). There was no significant difference between the two groups during the other weeks. Additionally, there was an inverse correlation between proliferation and chronological age, irrespective of the stage of the cycle. the PI of COC (p = 0.175) and natural cycles (p = 0.466) were not statistically different in younger patients. COC users have increased proliferative activity at the beginning of the menstrual cycle. This alteration in the pattern of proliferative activity may relate to the increased risk of breast cancer that has been associated with COCs.Federal University of São PauloUniversidade Federal de São Paulo, Dept Gynecol, Mastol Div, São Paulo, BrazilStanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USAAPC Pathol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Gynecol, Mastol Div, São Paulo, BrazilWeb of SciencKeywords
This publication has 36 references indexed in Scilit:
- Safety concerns and health benefits associated with oral contraceptionAmerican Journal of Obstetrics and Gynecology, 2004
- Hormonal content and potency of oral contraceptives and breast cancer risk among young womenBritish Journal of Cancer, 2003
- Estrogen and the Risk of Breast CancerNew England Journal of Medicine, 2001
- Effects of Oral Contraceptives on Breast Epithelial ProliferationBreast Cancer Research and Treatment, 2001
- Pharmacodynamics of Oestrogens and ProgestogensCephalalgia, 2000
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Oral contraceptives and breast cancerBMJ, 1996
- Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studiesThe Lancet, 1996
- Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factorsBreast Cancer Research and Treatment, 1996
- Oral contraceptive use influences resting breast proliferationHuman Pathology, 1989